Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

738390.pdf (3.13 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-04-04

Llicència de publicació

cc by (c) Riederer, Stephanie et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/202057

Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41417-023-00610-5

Resum

cGAMP-specific nucleases (poxins) are a recently described family of proteins dedicated to obstructing cyclic GMP-AMP synthase signaling (cGAS), an important sensor triggered by cytoplasmic viral replication that activates type I interferon (IFN) production. The B2R gene of vaccinia viruses (VACV) codes for one of these nucleases. Here, we evaluated the effects of inactivating the VACV B2 nuclease in the context of an oncolytic VACV. VACV are widely used as anti-cancer vectors due to their capacity to activate immune responses directed against tumor antigens. We aimed to elicit robust antitumor immunity by preventing viral inactivation of the cGAS/STING/IRF3 pathway after infection of cancer cells. Activation of such a pathway is associated with a dominant T helper 1 (Th1) cell differentiation of the response, which benefits antitumor outcomes. Deletion of the B2R gene resulted in enhanced IRF3 phosphorylation and type I IFN expression after infection of tumor cells, while effective VACV replication remained unimpaired, both in vitro and in vivo. In syngeneic mouse tumor models, the absence of the VACV cGAMP-specific nuclease translated into improved antitumor activity, which was associated with antitumor immunity directed against tumor epitopes.

Matèries

Immunitat, Animals, Interferó, Nucleòtids

Matèries (anglès)

Immunity, Animals, Interferon, Nucleotides

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)

Citació

RIEDERER, Stephanie, et al. Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease. Cancer Gene Therapy. 2023. Vol. 30, num. 7, pags. 1029-1039. ISSN 0929-1903. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/202057

Exportar metadades

JSON - METS

Compartir registre